Table 3 Demographic and clinical characteristics of HBV patients receiving NA therapy in Study 2 (n = 51).
Time points | Baseline | 48 weeks | P value |
|---|---|---|---|
Median (IQR) | Median (IQR) | ||
Age, years | 56 (48–71) | – | – |
Male, n (%) | 27 (52.9%) | – | – |
PLT, × 104/µL | 18.4 (14.6–23.9) | 19.0 (15.9–22.6) | 0.313 |
Alb, g/dL | 4.0 (3.7–4.3) | 4.2 (3.8–4.5) | 0.177 |
T. Bil, mg/dL | 0.7 (0.5–0.9) | 0.7 (0.5–1.0) | 0.776 |
AST, U/L | 35 (25–62) | 24 (18–30) | < 0.001 |
ALT, U/L | 32 (25–92) | 17 (14–24) | < 0.001 |
TSP2, ng/mL | 32.8 (25.3–45.7) | 24.1 (20.0–33.0) | < 0.001 |
HBsAg, log IU/mL | 3.34 (2.85–3.77) | 3.26 (2.51–3.66) | 0.005 |
HBeAg ( +), n (%) | 28 (54.9%) | 25 (49.0%) | 0.552 |
HBV-DNA, log IU/mL | 5.8 (3.7–8.1) | N/D (N/D-2.1) | < 0.001 |
NA regimen, ETV:TDF:TAF | 19:4:28 | – | – |
